|
|
Blood, 15 April 2005, Vol. 105, No. 8, pp. 3079-3086.
Prepublished online as a Blood First Edition Paper on January 6, 2005; DOI 10.1182/blood-2004-10-3867.
 Previous Article | Table of Contents | Next Article 
GENE THERAPY
Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy
Lili Wang,
Roberto Calcedo,
Timothy C. Nichols,
Dwight A. Bellinger,
Aaron Dillow,
Inder M. Verma, and
James M. Wilson
From the Gene Therapy Program, Department of Medicine, Division of Medical Genetics, University of Pennsylvania, Philadelphia, PA; the Department of Pathology and Laboratory Medicine, University of North Carolina Chapel Hill, NC; and the Laboratory of Genetics, The Salk Institute, La Jolla, CA.
Adeno-associated virus 8 (AAV8), a new member of the AAV family isolated from nonhuman primates, is an attractive candidate for hepatic gene transfer applications because of 10- to 100-fold improved transduction efficiency in mouse liver models. Additionally, AAV8 has lesser frequency of pre-existing immunity in humans. These properties could solve some of the problems associated with AAV2 vectors. The benefits of AAV8 demonstrated in mouse models, however, have not been confirmed in larger animals. In this study, we evaluate the efficacy and safety of AAV2/8 vector in both naive and AAV2-pretreated hemophilia B dogs. Two naive hemophilia B dogs that received a single intraportal administration of AAV2/8 vector have achieved sustained expression of 10% and 26% of normal levels of canine factor IX (cFIX) for more than a year. In an AAV2-pretreated hemophilia B dog, cFIX expression increased from less than 1% to 16% of normal levels when treated with an AAV2/8 vector, and a high level of expression has lasted for more than 2 years. No significant liver toxicity or cFIX-specific antibodies have been detected in these animals. Studies here have demonstrated the safety and improved efficacy of AAV2/8 vector in large-animal models for liver-directed gene therapy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. Lu and S. Song
Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors
PNAS,
October 6, 2009;
106(40):
17158 - 17162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Mays, L. H. Vandenberghe, R. Xiao, P. Bell, H.-J. Nam, M. Agbandje-McKenna, and J. M. Wilson
Adeno-Associated Virus Capsid Structure Drives CD4-Dependent CD8+ T Cell Response to Vector Encoded Proteins
J. Immunol.,
May 15, 2009;
182(10):
6051 - 6060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Margaritis, E. Roy, M. N. Aljamali, H. D. Downey, U. Giger, S. Zhou, E. Merricks, A. Dillow, M. Ezban, T. C. Nichols, et al.
Successful treatment of canine hemophilia by continuous expression of canine FVIIa
Blood,
April 16, 2009;
113(16):
3682 - 3689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Grimm, J. S. Lee, L. Wang, T. Desai, B. Akache, T. A. Storm, and M. A. Kay
In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses
J. Virol.,
June 15, 2008;
82(12):
5887 - 5911.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-J. Nam, M. D. Lane, E. Padron, B. Gurda, R. McKenna, E. Kohlbrenner, G. Aslanidi, B. Byrne, N. Muzyczka, S. Zolotukhin, et al.
Structure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector
J. Virol.,
November 15, 2007;
81(22):
12260 - 12271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lin, Y. Zhi, L. Mays, and J. M. Wilson
Vaccines Based on Novel Adeno-Associated Virus Vectors Elicit Aberrant CD8+ T-Cell Responses in Mice
J. Virol.,
November 1, 2007;
81(21):
11840 - 11849.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. High
Update on Progress and Hurdles in Novel Genetic Therapies for Hemophilia
Hematology,
January 1, 2007;
2007(1):
466 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Limberis and J. M. Wilson
Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered
PNAS,
August 29, 2006;
103(35):
12993 - 12998.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kitajima, D. H.L. Marchadier, G. C. Miller, G.-p. Gao, J. M. Wilson, and D. J. Rader
Complete Prevention of Atherosclerosis in ApoE-Deficient Mice by Hepatic Human ApoE Gene Transfer With Adeno-Associated Virus Serotypes 7 and 8
Arterioscler Thromb Vasc Biol,
August 1, 2006;
26(8):
1852 - 1857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Jiang, D. Lillicrap, S. Patarroyo-White, T. Liu, X. Qian, C. D. Scallan, S. Powell, T. Keller, M. McMurray, A. Labelle, et al.
Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs
Blood,
July 1, 2006;
108(1):
107 - 115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cardone, V. A. Polito, S. Pepe, L. Mann, A. D'Azzo, A. Auricchio, A. Ballabio, and M. P. Cosma
Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery
Hum. Mol. Genet.,
April 1, 2006;
15(7):
1225 - 1236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Grimm, K. Pandey, H. Nakai, T. A. Storm, and M. A. Kay
Liver Transduction with Recombinant Adeno-Associated Virus Is Primarily Restricted by Capsid Serotype Not Vector Genotype
J. Virol.,
January 1, 2006;
80(1):
426 - 439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
